The Department of Health and Human Services, through the Centers for Medicare and Medicaid Services, announced the selection of 15 additional drugs to be covered by Medicare Part D for price negotiation. In a statement, the agency announced that, in accordance with the Inflation Control Law, negotiations with participating pharmaceutical companies for these 15 medicines will take place in 2025, and the negotiated prices will take effect in 2027. The list of medicines selected for the second cycle of negotiations is as follows: Novo Nordisk (NVO) Ozempic, Libersus, Wigovy, GSK(GSK) Trelegy Ellipta, Pfizer (PFE) Standi, Bristol Myers (BMY) Pomalyst, Pfizer (PFE)’s Ibrance, Boehringer Ingleheim’s Ofev, AbbVie (ABV) and Ironwood’s (IRWD) Lindseth, AstraZeneca’s (AZN) Calquence, Teva(TEVA) of Orsted, GSK and Theravance (TBPH) Breo Ellipta, Boehringer’s Tradjenta, Salix (BHC) Xifaxan, AbbVie’s Vraylar, Merck’s (MRK) Janumet and Amgen (AMGN) Otezla. Companies with selected medicines have until February 28 to decide whether to participate in negotiations.
It was first published The Fly – The ultimate source of real-time financial news that moves the markets. Try it now >>
See today’s best performing stocks on TipRanks >>
Read more about NVO:
